GeneDx Holdings Corp.'s filings document financial results and operating disclosures for a genomics diagnostics company focused on rare disease testing. Form 8-K reports furnish quarterly and annual results, earnings presentations, preliminary revenue and testing-volume guidance, changes in statement presentation, and modifications to non-GAAP financial measure methodology.
The filing record also covers capital structure and governance matters, including a term loan agreement used to refinance existing debt, Class A common stock and Nasdaq-listed warrant disclosures, board composition changes, and definitive proxy materials. Proxy filings describe director elections, executive compensation, equity awards, stockholder voting matters, and related corporate governance policies.
GeneDx Holdings Corp. (WGS) reported that Chief Executive Officer Katherine Stueland exercised 18,750 Restricted Stock Units on September 16, 2026, receiving an equal number of shares of Class A Common Stock for no cash consideration as the RSUs settled one-for-one into common shares.
On the same date, she sold an aggregate of 10,501 shares of Class A Common Stock at weighted average prices between $94.23 and $99.305 per share pursuant to a sell to cover transaction to satisfy tax withholding obligations in connection with the RSU vesting, which the company states was not a discretionary sale. Following these sales, she beneficially owned 115,476 shares of Class A Common Stock, RSUs covering up to 280,228 shares, and options to purchase up to 107,610 shares, all vesting according to their terms. No Rule 10b5-1 trading plan is reported.
GeneDx Holdings Corp. (WGS) reported insider activity by Chief Financial Officer Kevin Feeley on September 16, 2026 related to vesting RSUs and associated tax withholding. Feeley exercised 7,197 Restricted Stock Units, receiving an equal number of Class A Common shares for no cash consideration, then sold 3,728 shares in multiple open-market transactions strictly to cover tax withholding obligations under a pre-arranged “sell to cover” mechanism, which the company states did not represent a discretionary transaction by him. After these trades, he beneficially owned 44,945 shares of Class A Common Stock and also held RSUs covering up to 71,667 shares and options for up to 25,906 shares, all vesting according to their existing terms.
GeneDx Holdings Corp. (WGS) director Thomas Fuchs reported the settlement of 1,146 Restricted Stock Units into 1,146 shares of Class A Common Stock on September 17, 2026, for no cash consideration. After these transactions, he holds 1,146 common shares and 2,292 RSUs directly. No Rule 10b5-1 trading plan is reported.
GeneDx Holdings Corp. (WGS) reported that its chief executive officer, Katherine Stueland, had 6,547 Restricted Stock Units settle into the same number of shares of Class A Common Stock on September 9, 2026. Of these shares, 3,692 were sold in a broker-assisted "sell to cover" transaction at a weighted average price of $84.22 per share to satisfy tax withholding obligations and were not a discretionary sale. After this tax-related sale, she beneficially owned 107,227 shares of Class A Common Stock, held RSUs for up to 298,978 additional shares, and options to purchase up to 107,610 shares, all vesting according to their respective terms.
GeneDx Holdings Corp. (WGS) reported that Chief Financial Officer Kevin Feeley settled 2,462 Restricted Stock Units into an equal number of shares of Class A Common Stock on September 9, 2026. On the same day, he sold 1,285 shares in a sell-to-cover transaction at a weighted average price of $84.2179 per share to satisfy tax withholding obligations, which the company states was not a discretionary trade. Following this sale, he beneficially owned 41,476 shares of Class A Common Stock and held RSUs for up to 78,864 shares and options for up to 25,906 shares, all vesting according to their terms.
GeneDx Holdings Corp. (WGS) reported that its Chief Financial Officer, Kevin Feeley, settled 717 Restricted Stock Units into 717 shares of Class A Common Stock on September 1, 2026, for no cash consideration. On the same date, 372 of those shares were sold at a weighted average price of $83.839 per share solely to satisfy tax withholding obligations in a non-discretionary “sell to cover” transaction. After these events, Feeley beneficially owned 40,299 shares of Class A Common Stock, RSUs for up to 81,326 additional shares, and options for up to 25,906 shares, all vesting according to their existing terms.
GeneDx Holdings Corp. (WGS) received a notice that officer Kevin Feeley has filed to sell up to 5,410 shares of Class A common stock under Rule 144 through Morgan Stanley Smith Barney, with an approximate sale date of September 1, 2026 on NASDAQ.
The shares relate to anticipated vesting of restricted stock units in three tranches of 372, 1,284, and 3,754 shares in September 2026. Feeley previously sold 5,364 shares during June 2026 to cover tax withholding obligations from RSU vesting.
GeneDx Holdings Corp. (WGS) received a notice that reporting person Katherine Stueland plans to sell 14,243 shares of Class A common stock under Rule 144 through Morgan Stanley Smith Barney on NASDAQ. The planned sale relates to anticipated vesting of 3,686 RSU shares on September 9, 2026 and 10,557 RSU shares on September 16, 2026. Over the past three months, Stueland sold 14,140 shares of Class A common stock to cover tax withholding obligations from RSU vesting.
The Goldman Sachs Group, Inc. and its subsidiary Goldman Sachs & Co. LLC report beneficial ownership of Class A common stock of GENEDX HOLDINGS CORP. They report aggregate beneficial ownership of 1,733,592.38 shares, representing 5.8% of the class.
Both entities report 0 shares with sole voting and dispositive power and 1,733,499.38 shares with shared voting power and 1,733,509.38 shares with shared dispositive power. Ownership is reported by GS Group as a parent holding company, with the securities owned or deemed owned by Goldman Sachs & Co. LLC, a registered broker-dealer and investment adviser. The Goldman Sachs reporting units disclaim beneficial ownership in certain client accounts and investment entities as described.
GeneDx Holdings Corp. (WGS) received an amended Schedule 13G filing reporting that ARK Investment Management LLC and its CEO/CIO Catherine D. Wood beneficially own 1,581,810 shares of GeneDx common stock, representing 5.33% of the class.
ARK reports sole voting power over 1,493,030 shares and shared voting power over 22,855 shares. ARK has sole dispositive power over 1,581,810 shares. Catherine D. Wood reports shared voting power over 1,515,885 shares and shared dispositive power over 1,581,810 shares.